Canadian Bladder Cancer Network: Research in Bladder Cancer

Join CBCAN

We invite you to join CBCAN, no charge, by registering on-line.

By joining CBCAN this will allow you to join the Discussion Forum, download the Bladder Cancer Basics brochure, as well, we will keep you informed about future meetings in your area and will ensure that you receive our Newsletter when available

Bladder Cancer Facts

In 2010, Statistics Canada estimates that 7,100 people in Canada will be diagnosed with bladder cancer, making it the 6th most common cancer in Canada (5th most common among men, with 5,300 cases and 12th most common among women with 1,800 cases).

With a recurrence rate of nearly 80%, bladder cancer is the most expensive cancer to treat on a per patient basis, and the high recurrence rate raises many issues affecting quality of life because of its persistence

Research in Bladder Cancer

Members of the Canadian Bladder Cancer Network - Research Arm

Wassim Kassouf, MD, CM, FRCSC (McGill University), Founding Member, Chair of CBCAN Research Arm

Yves Fradet, MD, FRCSC (Laval University)

Joseph Chin, (University of Western Ontario)

Louis Lacombe (Laval University)

Armen Aprikian (McGill University)

Michael Jewett (University of Toronto)

Alexander Zlotta (University of Toronto)

Jonathan Izawa (University of Western Ontario)

Ilias Cagiannos (University of Ottawa)

Jean-Baptiste Lattouf (University of Montreal)

Bobby Shayegan (McMaster University)

Darrel Drachenberg (University of Manitoba)

Eric Estey (University of Alberta)

Alan So (University of British Columbia)

Peter Black (University of British Columbia)

Ricardo Rendon (Dalhousie University)

Dr. Wassim Kassouf, Research Chair

After medical school and residency at McGill University, Dr Wassim Kassouf completed a urologic oncology fellowship at M. D. Anderson Cancer Center in Houston, Texas. He then arrived on faculty in August 2006 as an assistant professor in urology at the McGill University Health Center, Montreal, Canada. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and renal cancer. more»